As confirmation of our hypothesis, a phase 2 trial investigating a response to the drug temozolomide in metastatic SDH-deficient GIST to improve patient outcomes was recently launched and is ongoing (ClinicalTrials.gov/NCT03556384). This evidence concerns the gene SDHB and gastrointestinal stromal tumor.